

IN THE CLAIMS

Please revise pending Claims 1, 6-35, 42 and 46-74, as follows:

1. (Currently Amended) A combination comprising a first amount of ~~an aldosterone receptor antagonist~~ eplerenone, and a second amount of a beta-adrenergic antagonist, wherein said ~~aldosterone receptor antagonist~~ eplerenone and beta-adrenergic antagonist together comprise a therapeutically-effective amount of said ~~aldosterone receptor antagonist~~ eplerenone and said beta-adrenergic antagonist, and

~~wherein said aldosterone receptor antagonist is selected from the group consisting of eplerenone and spironolactone, and~~

wherein said beta-adrenergic antagonist is selected from the group consisting of acebutolol, alprenolol, ~~amosulalol~~, ~~aretinolol~~, atenolol, befunolol, bevantolol, bisoprolol, bopindolol, ~~bucumolol~~, bucindolol, bunitrolol, ~~butofilolol~~, carteolol, carvedilol, celiprolol, ~~eleranolol~~, ~~indenolol~~, labetalol, ~~levoprolol~~, ~~mepindolol~~, metipranolol, metoprolol, nadolol, nebivolol, ~~nifenalol~~, oxprenolol, penbutolol, pindolol, propranolol, sotalol, timolol, ~~toprol~~, ~~viskenit~~, ~~Ace 9369~~, ~~AMO 140~~, ~~betaxolol~~, ~~capsinolol~~, ~~carazolol~~, ~~CP 331684~~, ~~diprafenone~~, ~~ersentilide~~, ~~esmolol~~, ~~esprelol~~, ~~Fr 172516~~, ~~ISV 208~~, ~~L 653328~~, ~~laniolol~~, and ~~levobunolol~~, ~~LM 2616~~, ~~nipradilol~~, ~~Pharmaprojects No 5279~~, ~~S atenolol~~, ~~SB 226552~~, ~~SR 58894A~~, ~~SR 59230A~~, ~~talinolol~~, ~~tertatolol~~, ~~tilisolol~~, ~~TZC 5665~~, ~~UK 1745~~, ~~xamoterol~~, and ~~YM 430~~.

2-8. (Cancelled)

9. (Currently Amended) The combination of Claim 7 1 further characterized by said beta-adrenergic antagonist and said ~~epoxy steroidal aldosterone receptor antagonist~~ eplerenone being present in said combination in a weight ratio range from about one-to-one to about one-to-twenty of said beta-adrenergic antagonist to said ~~aldosterone receptor antagonist~~ eplerenone.

10. (Original) The combination of Claim 9 wherein said weight ratio range is from about one-to-five to about one-to-fifteen.

11. (Original) The combination of Claim 10 wherein said weight ratio range is about one-to-ten.

12. (Currently Amended) The combination of Claim 6 1 wherein the beta-adrenergic antagonist comprises carvedilol or a pharmaceutically-acceptable salt thereof.

13. (Currently Amended) The combination of Claim 6 1 wherein the beta-adrenergic antagonist comprises metoprolol or a pharmaceutically-acceptable salt thereof.

14. (Currently Amended) The combination of Claim 6 1 wherein the beta-adrenergic antagonist comprises bisoprolol or a pharmaceutically-acceptable salt thereof.

15. (Currently Amended) The combination of Claim 6 1 wherein the beta-adrenergic antagonist comprises bucindolol or a pharmaceutically-acceptable salt thereof.

16. (Currently Amended) The combination of Claim 6 1 wherein the beta-adrenergic antagonist comprises propranolol or a pharmaceutically-acceptable salt thereof.

17. (Currently Amended) The combination of Claim 6 1 wherein the beta-adrenergic antagonist comprises esmolol or a pharmaceutically-acceptable salt thereof.

18. (Currently Amended) The combination of Claim 6 1 wherein the beta-adrenergic antagonist comprises acebutolol or a pharmaceutically-acceptable salt thereof.

19. (Currently Amended) The combination of Claim 6 1 wherein the beta-adrenergic antagonist comprises sotalol or a pharmaceutically-acceptable salt thereof.

20. (Currently Amended) The combination of Claim 6 1 wherein the beta-adrenergic antagonist comprises labetalol or a pharmaceutically-acceptable salt thereof.

21-41. (Cancelled)

42. (Currently Amended) A pharmaceutical composition comprising a first amount of ~~an aldosterone receptor antagonist~~ eplerenone, a second amount of a beta-adrenergic antagonist and a pharmaceutically acceptable carrier, wherein said first amount and said second amount together comprise a therapeutically-effective amount of said ~~aldosterone receptor antagonist~~ eplerenone and said beta-adrenergic antagonist, and

~~wherein said aldosterone receptor antagonist is selected from the group consisting of eplerenone and spironolactone, and~~

wherein said beta-adrenergic antagonist is selected from the group consisting of acebutolol, ~~alprenolol, amesulalol, aretinelol, atenolol, befunolol, bevantolol, bisoprolol, bopindolol, bucumolol, bucindolol, bunitrolol, butofilolol, carteolol, carvedilol, celiprolol, eleranolol, indenolol, labetalol, levoprolol, mepindolol, metipranolol, metoprolol, nadolol, nebivolol, nifenalol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, timolol, toprol, viskenit, Ace 9369, AMO-140, betaxolol, capsinolol, carazolol, CP 331684, diprafenone, ersentilide, esmolol, esprolol, Fr 172516, ISV 208, L 653328, lanielol, and levobunolol, LM 2616, nipradilol, Pharmaprojects No 5279, S atenolol, SB 226552, SR 58894A, SR 59230A, talinolol, tertatolol, tilisolol, TZC 5665, UK 1745, xamoterol, and YM 430.~~

43-47. (Cancelled)

48. (Currently Amended) A therapeutic method for treating a cardiovascular disorder, said method comprising administering to a subject susceptible to or afflicted with such disorder a first amount of ~~an aldosterone receptor antagonist~~ eplerenone and a second amount of a beta-adrenergic antagonist,

wherein said first amount and said second amount together comprise a therapeutically-effective amount of said ~~aldosterone-receptor antagonist~~ eplerenone and said beta-adrenergic antagonist, and

wherein said ~~aldosterone-receptor antagonist~~ is selected from the group consisting of ~~eplerenone and spironolactone~~, and said beta-adrenergic antagonist is selected from the group consisting of acebutolol, ~~alprenolol~~, ~~amosulalel~~, ~~aretinolel~~, atenolol, ~~befunolel~~, ~~bevantolel~~, bisoprolol, bopindolol, ~~bucumolel~~, bucindolol, ~~bunitrolel~~, ~~butofilelel~~, carteolol, carvedilol, celiprolol, ~~cleranelel~~, ~~indenolel~~, labetalol, ~~leveprolel~~, ~~mepindelel~~, metipranolol, metoprolol, nadolol, nebivolol, ~~nifenalol~~, oxprenolol, penbutolol, pindolol, propranolol, sotalol, timolol, ~~toprol~~, ~~viskenit~~, ~~Ace 9369~~, ~~AMO-140~~, betaxolol, ~~eapsinolel~~, ~~carazolel~~, ~~CP 331684~~, ~~diprafenone~~, ~~ersentilide~~, ~~esmolol~~, ~~esprolel~~, ~~Fr 172516~~, ~~ISV 208~~, ~~L 653328~~, ~~laniolel~~, and levobunolol, ~~LM 2616~~, ~~nipradilol~~, ~~Pharmaprojects No 5279~~, ~~S-atenalol~~, ~~SB 226552~~, ~~SR 58894A~~, ~~SR 59230A~~, ~~talinolel~~, ~~tertatolel~~, ~~tilisolel~~, ~~TZC 5665~~, ~~UK 1745~~, ~~xamoterol~~, and ~~YM 430~~.

49. (Currently Amended) The method of Claim 48, wherein said cardiovascular disorder is selected from the group consisting of hypertension, and congestive heart failure, ~~cirrrosis and ascites~~.

50. (Original) The method of Claim 49, wherein said cardiovascular disorder is hypertension.

51. (Original) The method of Claim 49, wherein said cardiovascular disorder is congestive heart failure.

52. (Cancelled)

53. (Currently Amended) The pharmaceutical composition of Claim 46 42 wherein the beta-adrenergic antagonist comprises carvedilol or a pharmaceutically-acceptable salt thereof.

54. (Currently Amended) The pharmaceutical composition of Claim 46 42 wherein the beta-adrenergic antagonist comprises metoprolol or a pharmaceutically-acceptable salt thereof.

55. (Currently Amended) The pharmaceutical composition of Claim 46 42 wherein the beta-adrenergic antagonist comprises bisoprolol or a pharmaceutically-acceptable salt thereof.

56. (Currently Amended) The pharmaceutical composition of Claim 46 42 wherein the beta-adrenergic antagonist comprises bucindolol or a pharmaceutically-acceptable salt thereof.

57. (Currently Amended) The pharmaceutical composition of Claim 46 42 wherein the beta-adrenergic antagonist comprises propranolol or a pharmaceutically-acceptable salt thereof.

58. (Currently Amended) The pharmaceutical composition of Claim 46 42 wherein the beta-adrenergic antagonist comprises esmolol or a pharmaceutically-acceptable salt thereof.

59. (Currently Amended) The pharmaceutical composition of Claim 46 42 wherein the beta-adrenergic antagonist comprises acebutolol or a pharmaceutically-acceptable salt thereof.

60. (Currently Amended) The pharmaceutical composition of Claim 46 42 wherein the beta-adrenergic antagonist comprises sotalol or a pharmaceutically-acceptable salt thereof.

61. (Currently Amended) The pharmaceutical composition of Claim 46 42 wherein the beta-adrenergic antagonist comprises labetalol or a pharmaceutically-acceptable salt thereof.

62. (Cancelled)

63. (Currently Amended) The method of Claim 48 wherein said ~~aldosterone receptor antagonist~~ eplerenone and said beta-adrenergic antagonist are administered in a sequential manner.

64. (Currently Amended) The method of Claim 48 wherein said ~~aldosterone receptor antagonist~~ eplerenone and said beta-adrenergic antagonist are administered in a substantially simultaneous manner.

65-74. (Cancelled)